Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia

Figures & data

Figure 1. Model structure.

Table 1. Total treatment costs

		Daily dose	Mean cost per unit
Treatments
Meropenem, g		6	$6.53
Colistin, million unit (MIU)	Loading dose	3*	$11.83
	Maintenance dose	4.5*
CAZ-AVI, g		7.5	$40.23
Additional treatments
Tigecycline, mg		100	$21,61
Fosfomycin, g		12	$2,29
*Average weight 60 kg

Table 2. Costs inputs

		Mean		SD
Hospitalization
Ward		$35		$32
ICU		$313		$207
Adverse event
Renal failure		$426		$145
Dialysis		$1,197		$189
Paraclinics
Colistin-meropenem		$15		$11
CAZ-AVI		$5		$4

Table 3. Events per 1,000 patients at the 30 days of follow-up

	CAZ-AVI	Colistin-meropenem	Difference (%)
Death	92	320	228 (71.2)
Alive in hospital	724	607	117 (19.1)
Discharge home	184	73	111 (52.1)
Additional antibiotic	630	940	310 (32.3)
Renal failure	50	130	80 (61.8)

Table 4. Total cost per 1,000 patients at the 30 days of follow-up

	CAZ-AVI	Colistin-meropenem	Difference
Treatment	3,276	755	2,521
Renal failure	43	113	−69
Hospital stay	4,964	4,098.82	865
Total	8,284	4,966.44	3317

Figure 2. Acceptability curve.